Xeris Biopharma Holdings, Inc. XERS
15.20 USD +2.12 (+16.21%)
At closeNov 6, 2026, 5:35 PM EST
15.13 -0.07 -0.46%
After hours · Nov 6, 5:35 PM ET
13.53 Day range 15.21
5.25 52-week range 15.21
- YTD
- +93.63%
- 1 year
- +97.15%
- Market cap
- 2.77B
- Revenue (ttm)
- 335.41M
- Profit margin
- -5.12%
- EPS (ttm)
- -0.03
- Shares out
- 182.32M
- Forward P/E
- 77.29
- YTD return
- +93.63%
- 1-year return
- +97.15%
- Volume
- 7.89M
- Avg volume
- 2.54M
- Open
- 13.79
- Previous close
- 13.08
- Day's range
- 13.53 – 15.21
- 52-week range
- 5.25 – 15.21
- Beta
- 0.84
- Price target
- 12.86 (-15.4%)
- Earnings date
- Mar 1, 2027
1m +4.65 (+44.08%)
Key statistics
- Enterprise value
- 2.07B
- PEG ratio
- 0.00
- Price / sales
- 8.26
- Price / book
- 185.37
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 28.70%
- Free cash flow
- 52.45M
- Total cash
- 121.75M
- Total debt
- 289.44M
- Return on equity
- 0.00%
- Short % of float
- 4.55%
- 50-day average
- 9.49
- 200-day average
- 7.57
Analyst view
Price target (mean) 12.86 -15.4% downside
Now 15.20
- Target (low)
- 8.00
- Target (mean)
- 12.86
- Target (high)
- 18.00
Ratings (0m) 7 6 buy · 1 hold · 0 sell
- Strong buy1
- Buy5
- Hold1
- Sell0
- Strong sell0
Next earnings
Mar 1, 2027
Expected Mar 1, 2027. Consensus EPS estimate 0.03333.
Financials — quick view
XERS Revenue — quarterly 92.10M
XERS Net income — quarterly -31.10M
XERS EPS — quarterly -0.18
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Mar 1, 2027 | Dec 30, 2026 | 0.03 | — | — | — |
| Nov 5, 2026 | Sep 30, 2026 | 0.03167 | 0.06 | +0.03 | +89.45% |
| Aug 6, 2026 | Jun 30, 2026 | 0.01214 | -0.18 | -0.19 | -1,582.70% |
| May 7, 2026 | Mar 31, 2026 | -0.00274 | 0.01 | +0.01 | +464.96% |
| Mar 2, 2026 | Dec 31, 2025 | 0.03 | 0.06 | +0.03 | +100.00% |
| Nov 6, 2025 | Sep 30, 2025 | 0.01 | 0.0035 | -0.01 | -65.00% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 6, 2026 | Oppenheimer | reit | Outperform | Outperform |
| Nov 6, 2026 | Piper Sandler | reit | Neutral | Neutral |
| Nov 6, 2026 | HC Wainwright & Co. | main | Buy | Buy |
| Oct 6, 2026 | Barclays | main | Overweight | Overweight |
| Sep 10, 2026 | Leerink Partners | main | Outperform | Outperform |
| Aug 20, 2026 | Barclays | main | Overweight | Overweight |
About Xeris Biopharma Holdings, Inc.
Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. It offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase 3 clinical trial for the treatment of hypothyroidism. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- United States
- Website
- xerispharma.com
News
Oppenheimer Reiterates Outperform on Xeris Biopharma Holdings, Raises Price Target to $21 
Piper Sandler Reiterates Neutral on Xeris Biopharma Holdings, Raises Price Target to $12 
HC Wainwright & Co. Maintains Buy on Xeris Biopharma Holdings, Raises Price Target to $18 
Xeris Biopharma (NASDAQ:XERS) Reaches New 12-Month High on Better-Than-Expected Earnings 
12 Health Care Stocks Moving In Thursday's Intraday Session 
Nasdaq Tumbles 4.5%; Cardinal Health Shares Gain After Upbeat Q1 Earnings 
Xeris Biopharma (XERS) Surpasses Q3 Earnings and Revenue Estimates 
Xeris Biopharma (XERS) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates 
Motorola Solutions, Sezzle, Unity Software, Toyota Motor And Other Big Stocks Moving Higher On Thursday 
Xeris Biopharma Holdings Q3 2026 Earnings Call Transcript
Your note
Sign in to keep a note on XERS — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BORMANN-KENNEDY BARBARA-JEAN ANNE | Director | Stock Award(Grant) | Jun 3, 2026 | 150,693 |
| HECHT BETH P | Officer | Sale | Nov 1, 2026 | 1,086,130 |
| JOHNSON JOHN H. | Director | Sale | Dec 18, 2025 | 698,083 |
| KONG GARHENG | Director | Stock Award(Grant) | Jun 3, 2026 | 238,337 |
| MCCULLOCH KEVIN | President | Sale | Nov 1, 2026 | 1,609,210 |
| NGUYEN ANH TU | Officer | Stock Award(Grant) | Jan 29, 2026 | 431,534 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 7.97% | 14,525,539 | 220.79M | Jun 29, 2026 |
| Shaw D.E. & Co., Inc. | 4.28% | 7,804,758 | 118.63M | Jun 29, 2026 |
| Vanguard Capital Management LLC | 4.03% | 7,340,229 | 111.57M | Jun 29, 2026 |
| State Street Corporation | 2.64% | 4,821,566 | 73.29M | Jun 29, 2026 |
| Geode Capital Management, LLC | 2.59% | 4,718,183 | 71.72M | Jun 29, 2026 |
| Nuveen, LLC | 2.41% | 4,385,141 | 66.65M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.85% | 5,193,656 | 78.94M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.42% | 4,417,108 | 67.14M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 1.09% | 1,986,461 | 30.19M | Jun 29, 2026 |
| College Retirement Equities Fd.-College Retirement Equities Fd. - Tota | 1.07% | 1,951,890 | 29.67M | Jun 29, 2026 |
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 1.03% | 1,872,201 | 28.46M | Aug 30, 2026 |
| iShares Trust-iShares Russell 2000 Growth ETF | 0.88% | 1,595,993 | 24.26M | Sep 29, 2026 |